CCHT(SZ:000661) Qian Zhan Wang·2026-02-27 09:16Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the clinical trial application of GenSci141 ointment, the world's first specific treatment for children's micropenis, marking a historic breakthrough in a long-neglected area of standard drug treatment [2][3]. Company Summary - The approval of GenSci141 ointment represents a shift from empirical medication to precision treatment for children's micropenis, providing the first clinically validated standard treatment option [3]. - The stock price of Changchun High-tech reacted strongly to the news, closing at 97.26 yuan per share on February 25, and reaching a peak of 108 yuan on February 26, with a cumulative increase of over 12% in two days, pushing the total market value beyond 40 billion yuan [2]. - The company maintains a cautious stance regarding the project, indicating that it is still in the early stages and that the drug has only received approval for clinical trials, with no confirmed timeline for market launch [3][4]. Industry Summary - The biopharmaceutical industry is a core component of China's strategic emerging industries, essential for public health, technological innovation, and enhancing the country's self-sufficiency in medicine [4]. - The Chinese biopharmaceutical market is projected to grow from 345.7 billion yuan in 2020 to 524.2 billion yuan by 2024, with expectations to exceed 800 billion yuan by 2028, maintaining an annual growth rate of 10%-12% [4]. - The industry value chain consists of upstream raw materials, midstream research and production, and downstream distribution and consumption, with the midstream segment holding the highest profit margins due to its technological barriers [6][8].